Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05144425
Other study ID # Elbasel
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date December 10, 2021
Est. completion date December 2022

Study information

Verified date November 2021
Source Assiut University
Contact Mohamed Elbasel Abdel Raheem, Bachelor
Phone 01091673453
Email dmbheba21@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of our study is to determine whether the use of a tourniquet during TKA would affect total measured blood loss , operation time, postoperative complications; hemoglobin concentration; limb swelling and postoperative pain.


Description:

Tourniquets are widely used in total knee arthroplasty (TKA) . TKA has been reported to be associated with significant blood loss which at times necessitates transfusion. Although the tourniquet is widely used by orthopedic surgeons, its role is controversial . Several studies have shown that using a tourniquet in TKA could reduce the total blood loss, while results from others indicated the opposite . Therefore the relationship between the use of a tourniquet and the total blood loss of patients undergoing TKA is still unclear. The use of a tourniquet is believed to be effective for decreasing intraoperative blood loss and creating a bloodless surgical field, which theoretically would facilitate the cementing technique and other surgical procedures. However, reactive blood flow reaches its peak within five minutes after the tourniquet has been released Complications reported as a consequence of tourniquet application are skin injury [skin abrasions, blisters, breaks , pressure necrosis], nerve injury, post tourniquet syndrome, Deep venous thrombosis, Postoperative pain, wound healing disorders and early infections


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date December 2022
Est. primary completion date October 2022
Accepts healthy volunteers No
Gender All
Age group 55 Years to 75 Years
Eligibility Inclusion Criteria: - any patient with knee osteoarthritis undergoing primary total knee arthroplasty Exclusion Criteria: 1. patients with hemorrhagic disease 2. patient with revision total knee arthroplasty 3. patient with history of vascular thrombosis 4. patients taking anti-platelet agents due to cardiovascular disease 5. patients with hemoglobin level below 10gm/dl

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
total knee arthroplasty with and without using pneumatic tourniquet
The randomization will be performed by a research fellow who will not be involved in patient care. All of the operations will be performed through the medial parapatellar approach by experienced knee surgeons. Drainage system will be used for 48 hours postoperative. In the tourniquet group, the tourniquet will be inflated to a pressure of systolic blood pressure plus 100 mm Hg and will be released after the joint capsule has been closed. hemostasis and then will be wrapped with elastic bandages. In the non-tourniquet group, the tourniquet will be wrapped around the thigh but will not be inflated during the surgery. The criterion for a blood transfusion will set as a hemoglobin (Hb) level of<8 g/dL or patient with symptomatic anemia.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

References & Publications (3)

Arthur JR, Spangehl MJ. Tourniquet Use in Total Knee Arthroplasty. J Knee Surg. 2019 Aug;32(8):719-729. doi: 10.1055/s-0039-1681035. Epub 2019 Mar 1. Review. — View Citation

Cai DF, Fan QH, Zhong HH, Peng S, Song H. The effects of tourniquet use on blood loss in primary total knee arthroplasty for patients with osteoarthritis: a meta-analysis. J Orthop Surg Res. 2019 Nov 8;14(1):348. doi: 10.1186/s13018-019-1422-4. Review. — View Citation

Nicolaiciuc S, Probst P, von Eisenhart-Rothe R, Burgkart R, Hube R. Modern Total Knee Arthroplasty (TKA): With Or Without a Tourniquet? Surg Technol Int. 2019 Nov 10;35:336-340. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary amount of perioperative blood loss in ml with and without using tourniquet during TKA Total measured blood loss will be calculated as the volume of the intraoperative blood loss plus the volume of postoperative visible blood loss from the hemovac drains and will be expressed as mL 48hr
Secondary post operative pain measured on VAS after TKA with and without using tourniquet Knee joint pain will be measured on a visual analog scale (VAS) (range, 0-10) pre-operatively and on the 3rd, 5th, 7th and 14th postoperative days [12]. A higher score on the VAS equates to a higher level of pain. 48hr
Secondary operative time in minutes with and without using tourniquet in TKA operative time in minutes will be calculated and compared the two groups operation time
Secondary hemoglobin level in gm/dl preoperative and postoperative Hemoglobin level will be measured pre-operatively and after 24hrs and 48 hrs post-operatively. Patients with Hb < 8 g/dl or those who have exhibited symptoms of acute anemia will receive blood transfusion therapy. The amount of blood transfused will be recorded. 48hrs
See also
  Status Clinical Trial Phase
Completed NCT02427711 - Reduced Total Blood Loss and Blood Transfusion in Non-Septic Revision Knee Arthroplasty Using a Bipolar Sealer N/A
Not yet recruiting NCT03310060 - Reducing Blood Loss Using Tisseel in TKA Phase 4
Recruiting NCT05504577 - Kaolin-based Hemostatic Gauze in Total Knee Arthroplasty Phase 4
Recruiting NCT04855877 - Oral Administration of Tranexamic Acid in Anterior Cruciate Ligament Surgery Reduce Postoperative Haemarthrosis Phase 4
Completed NCT02393300 - Comparison of Topical Versus Intravenous Tranexamic Acid in TKA Phase 3
Completed NCT04691362 - Noninferiority Oral Tranexamic Acid vs Intravenous Administration in Total Hip Arthroplasty Phase 4